XRAY

$12.22

Pre-MarketAs of Mar 17, 8:00 PM UTC

DENTSPLY SIRONA Inc.

Recent News

Simply Wall St.
Mar 18, 2026

How Investors Are Reacting To DENTSPLY SIRONA (XRAY) Launching a First-of-Its-Kind Dental MRI Platform

Dentsply Sirona and Siemens Healthineers recently received FDA clearance in the US for the MAGNETOM Free.Max Dental Edition, the first dental‑dedicated MRI system validated in a clinical trial for multiple dental specialties including endodontics, periodontics, TMJ, extractions, and orthodontics. This radiation‑free imaging technology, featuring a dental‑specific field of view and workflow times under 20 minutes, could reshape complex dental diagnostics for hospitals, large clinics, and...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 13, 2026

Is Dentsply Sirona Stock a Buy After a Company Director Purchased 15,000 Shares?

This global dental technology firm, with strong recurring revenues, reported a notable insider buy following a year of share price declines.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 12, 2026

3 Cash-Producing Stocks Walking a Fine Line

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 9, 2026

3 Stocks Under $50 Walking a Fine Line

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 8, 2026

How The Dentsply Sirona (XRAY) Story Is Shifting As Analysts Rework Valuation And Risks

The updated model lifts DENTSPLY SIRONA’s fair value estimate from US$12.97 to US$14.43, putting fresh focus on how the stock’s upside case is being recalibrated. This shift lines up with recent Street work, where several firms have moved price targets higher while keeping a mixed stance on how much execution risk remains. As you read on, you will see how these target changes fit into the evolving narrative and what to watch if you are tracking this story over time. Analyst Price Targets...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.